Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan

  • Authors:
    • Jing Sun
    • Yanfang Li
    • Xuying Sun
    • Youde Liu
    • Danxia Zheng
    • Lijuan Fan
  • View Affiliations

  • Published online on: July 3, 2019     https://doi.org/10.3892/etm.2019.7727
  • Pages: 1891-1898
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present cross‑sectional study aimed to assess hepatic fibrosis in chronic hepatitis B (CHB) patients with abdominal obesity and to explore the associated indicators. A total of 615 CHB patients were enrolled and 287 of them had abdominal obesity. The liver stiffness value was measured using Fibroscan. The diagnosis of liver fibrosis was confirmed by a liver stiffness value of >7.4 kPa, and a value of >10.6 kPa was considered to indicate advanced liver fibrosis. The Fibroscan results suggested that the liver stiffness value in patients with abdominal obesity was significantly higher than that in patients without abdominal obesity (9.94±11.59 vs. 7.47±7.58 kPa; P=0.002). The proportions of patients with liver fibrosis and advanced liver fibrosis among patients with abdominal obesity were significantly higher than those among patients without abdominal obesity (P=0.011). Multivariate logistic regression analysis indicated that a high aspartate aminotransferase (AST) level [odds ratio (OR)=2.991; P<0.001], smoking (OR=2.002; P=0.019) and diabetes mellitus (OR=2.047; P=0.029) were independent indicators for liver fibrosis in CHB patients with abdominal obesity. Furthermore, a high AST level (OR=1.024; P<0.001), alcohol consumption (OR=1.994; P=0.032) and diabetes mellitus (OR=1.977; P=0.045) were independent indicators for advanced hepatic fibrosis. The indicators associated with liver steatosis included high body weight (OR=1.113; P<0.001) and high diastolic blood pressure (OR=1.079; P=0.002). In conclusion, the present study indicated that abdominal obesity significantly exacerbates liver fibrosis in CHB patients. For CHB patients with abdominal obesity and a risk of developing liver fibrosis, priority screening and timely intervention should be provided.

References

1 

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al: Asian-pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 10:1–98. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Xue X, Cai S, Ou H, Zheng C and Wu X: Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence. 11:85–93. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Wu X, Cai S, Li Z, Zheng C, Xue X, Zeng J and Peng J: Potential effects of telbivudine and entecavir on renal function: A systematic review and meta-analysis. Virol J. 13:642016. View Article : Google Scholar : PubMed/NCBI

4 

Peng J, Yin J, Cai S, Yu T and Zhong C: Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: Results from a 1 year follow-up study. Patient Prefer Adherence. 9:41–45. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Lok AS and McMahon BJ: Chronic hepatitis b: Update 2009. Hepatology. 50:661–662. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Gutierrez-Fisac JL, Guallar-Castillon P, Leon-Munoz LM, Graciani A, Banegas JR and Rodriguez-Artalejo F: Prevalence of general and abdominal obesity in the adult population of Spain, 2008–2010: The ENRICA study. Obes Rev. 13:388–392. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Zhai Y, Fang HY, Yu WT, Yu DM, Zhao LY, Liang XF and Zhao WH: Changes in waist circumference and abdominal obesity among chinese adults over a ten-year period. Biomed Environ Sci. 30:315–322. 2017.PubMed/NCBI

8 

Suder A, Janusz M, Jagielski P, Głodzik J, Pałka T, Cisoń T and Pilch W: Prevalence and risk factors of abdominal obesity in polish rural children. Homo. 66:357–368. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Lim J and Park HS: Trends in the prevalence of underweight, obesity, abdominal obesity and their related lifestyle factors in korean young adults, 1998–2012. Obes Res Clin Pract. 12:358–364. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Cai S, Ou Z, Liu D, Liu L, Liu Y, Wu X, Yu T and Peng J: Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome. United European Gastroenterol J. 6:558–566. 2018. View Article : Google Scholar : PubMed/NCBI

11 

Ou H, Cai S, Liu Y, Xia M and Peng J: A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Therap Adv Gastroenterol. 10:207–217. 2017. View Article : Google Scholar : PubMed/NCBI

12 

European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), : EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 64:1388–1402. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Besharat S, Poustchi H, Mohamadkhani A, Roshandel G, Freedman ND, Merat S and Malekzadeh R: Central obesity and advanced liver stiffness in hepatitis b: Result from golestan hepatitis b cohort study. Arch Iran Med. 18:562–566. 2015.PubMed/NCBI

14 

Wong L, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, Chan HY, Tse CH and Wong VW: Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 39:883–893. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Alberti KG, Zimmet P and Shaw J: The metabolic syndrome-a new worldwide definition. Lancet. 366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Chen YP, Liang XE, Zhang Q, Peng J, Zhu YF, Wen WQ and Hou JL: Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B. J Gastroenterol Hepatol. 27:1219–1226. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Cai S, Cao J, Yu T, Xia M and Peng J: Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore). 96:e70212017. View Article : Google Scholar : PubMed/NCBI

18 

Xue X and Cai S: Comment on ‘assessment of liver stiffness in pediatric fontan patients using transient elastography’. Can J Gastroenterol Hepatol. 2016:93439602016. View Article : Google Scholar : PubMed/NCBI

19 

Cai S, Yu T, Jiang Y, Zhang Y, Lv F and Peng J: Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48 week result. Clin Exp Med. 16:429–436. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Cai SH, Lv FF, Zhang YH, Jiang YG and Peng J: Dynamic comparison between daan real-time PCR and cobas taqman for quantification of HBV DNA levels in patients with Chb. Bmc Infect Dis. 14:852014. View Article : Google Scholar : PubMed/NCBI

21 

Zeng J, Cai S, Liu J, Xue X, Wu X and Zheng C: Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis b. J Ultrasound Med. 36:261–268. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Cai SH, Lu SX, Liu LL, Zhang CZ and Yun JP: Increased expression of hepatocyte nuclear factor 4 alpha transcribed by promoter 2 indicates a poor prognosis in hepatocellular carcinoma. Therap Adv Gastroenterol. 10:761–771. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ and Yun JP: HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 11:1225–1240. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Cai S, Li Z, Yu T, Xia M and Peng J: Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist. 11:469–477. 2018. View Article : Google Scholar : PubMed/NCBI

25 

Roulot D, Roudot-Thoraval F, Nkontchou G, Kouacou N, Costes JL, Elourimi G, Le Clesiau H, Ziol M and Beaugrand M: Concomitant screening for liver fibrosis and steatosis in french type 2 diabetic patients using Fibroscan. Liver Int. 37:1897–1906. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Peng J, Cai S, Yu T, Chen Y, Zhu Y and Sun J: Aspartate aminotransferase to platelet ratio index - a reliable predictor of therapeutic efficacy and improvement of Ishak score in chronic hepatitis B patients treated with nucleoside analogues. Scand J Clin Lab Invest. 76:133–142. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Corpechot C, Gaouar F, Chretien Y, Johanet C, Chazouilleres O and Poupon R: Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol. 56:218–224. 2012. View Article : Google Scholar : PubMed/NCBI

28 

van der Vaart H, Postma DS, Timens W and Ten HN: Acute effects of cigarette smoke on inflammation and oxidative stress: A review. Thorax. 59:713–721. 2004. View Article : Google Scholar : PubMed/NCBI

29 

Bijl M, Horst G, Limburg PC and Kallenberg CG: Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest. 31:550–553. 2001. View Article : Google Scholar : PubMed/NCBI

30 

Zeidel A, Beilin B, Yardeni I, Mayburd E, Smirnov G and Bessler H: Immune response in asymptomatic smokers. Acta Anaesthesiol Scand. 46:959–964. 2002. View Article : Google Scholar : PubMed/NCBI

31 

Ma Z, Hou T, Shi W, Liu W and He H: Inhibition of hepatocyte apoptosis: An important mechanism of corn peptides attenuating liver injury induced by ethanol. Int J Mol Sci. 16:22062–22080. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Kim WH, Hong F, Jaruga B, Hu Z, Fan S, Liang TJ and Gao B: Additive activation of hepatic NF-kappaB by ethanol and hepatitis B protein X (HBX) or HCV core protein: Involvement of TNF-alpha receptor 1-independent and -dependent mechanisms. FASEB J. 15:2551–2553. 2001. View Article : Google Scholar : PubMed/NCBI

33 

Xiao YB, Cai SH, Liu LL, Yang X and Yun JP: Decreased expression of peroxisome proliferator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma. Cancer Manag Res. 10:1781–1789. 2018. View Article : Google Scholar : PubMed/NCBI

34 

Jin X, Chen YP, Yang YD, Li YM, Zheng L and Xu CQ: Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One. 7:e341982012. View Article : Google Scholar : PubMed/NCBI

35 

Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, Chan HL, To KF and Wong VW: Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 32:667–676. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sun, J., Li, Y., Sun, X., Liu, Y., Zheng, D., & Fan, L. (2019). Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan. Experimental and Therapeutic Medicine, 18, 1891-1898. https://doi.org/10.3892/etm.2019.7727
MLA
Sun, J., Li, Y., Sun, X., Liu, Y., Zheng, D., Fan, L."Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan". Experimental and Therapeutic Medicine 18.3 (2019): 1891-1898.
Chicago
Sun, J., Li, Y., Sun, X., Liu, Y., Zheng, D., Fan, L."Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1891-1898. https://doi.org/10.3892/etm.2019.7727